Five lessons from biopharma companies’ data transformation journeys
Author: Sebastian Wurst, Director, OpenData Strategy, Europe As global biopharmas expand into new markets, they introduce more systems to handle…
Author: Sebastian Wurst, Director, OpenData Strategy, Europe As global biopharmas expand into new markets, they introduce more systems to handle…
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your…
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in…
Cell and gene therapies (CGT) offer hope to patients living with life-threatening conditions where limited treatment options may be available…
AI is revolutionizing drug discovery with its ability to analyze vast datasets. Particularly beneficial in the early drug discovery phase,…
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in…
One of the key advantages of blockchain is that it removes the need for patients to provide the same information…
The evolution of pharmaceutical manufacturing is driven largely by the rising demands facing the industry. Inflation, strict regulations and a…
Introduction Ion chromatography (IC), a highly sensitive technique for separating and quantifying ionic species, was introduced in the 1970s and…
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially…